文献速递胸部肿瘤

在爱尔兰新诊断晚期非小细胞肺癌患者中血浆优先二代测序的临床获益与成本:PLAN研究

Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study.
PubMed 文献 · Eur J Cancer · 2025-06-17

PLAN试验在爱尔兰四家癌症中心招募疑似III-IV期肺癌患者,评估影像学怀疑晚期NSCLC时即行液体活检基因分型(LBG)的可行性并构建微成本模型。138例入组,100例纳入主要分析,LBG完成率100%,组织活检基因分型(TBG)完成率68%;LBG较TBG中位报告时间缩短21天,配对可评估病例一致性90%,LBG成本€1135低于TBG€2404,总体节省€20,288。

要点

  • LBG在100例可评估患者中完成率100%,TBG完成率68%。
  • LBG较TBG中位报告时间缩短21天(z=-6.8,p<0.01)。
  • LBG成本€1135,低于TBG的€2404,总体节省€20,288。

核心结论

  • LBG较组织基因分型缩短新诊断NSCLC患者的基因组诊断时间,检出组织未报告的可靶向变异,并带来总体成本节省。

研究设计与样本

  • 先导临床试验(PLAN,NCT05542485),2023年8月至2024年7月从爱尔兰四家癌症中心招募影像学怀疑III-IV期肺癌患者。
  • LBG采用Archer LiquidplexTM NGS检测,微成本模型(MCM)考虑人员时间、耗材、资本成本及避免重复组织活检基因分型(TBG)或不适当全身治疗(如EGFR+ NSCLC使用免疫治疗)的节省。

主要发现

  • 共138例入组,38例排除于主要分析(鳞癌16例;SCLC 22例)。
  • 可评估患者中LBG完成100%(100/100);TBG完成68%(68/100;组织不足20%(20/100);ECOG PS下降12%(12/100))。
  • 因LBG报告可用,12%(12/100)患者避免重复组织活检。
  • LBG至收到基因组报告的中位日历天数较TBG缩短21天(z=-6.8,p<0.01),中位范围1-104天。
  • 68例同时有TBG和LBG的可评估配对病例一致性为90%(61/68);LBG检出5个可靶向变异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsma Genomic Testing in Advanced NSCLC; The PLAN trial, ClinicalTrials.gov Identifier: NCT05542485). METHODS: Patients with a radiologic suspicion of stage III-IV lung cancer were recruited from four cancer centres in Ireland between August 2023 and July 2024. LBG was performed using the Archer LiquidplexTM NGS assay. The MCM considered staff time, consumables and capital costs and savings from avoidance of repeat tissue biopsy genotyping (TBG) or inappropriate systemic therapy such as immunotherapy for EGFR + NSCLC. RESULTS: A total of 138 patients were enrolled in the study with 38 excluded from the primary analysis (Squamous=16; SCLC = 22). Of patients that were eligible, LBG was completed in 100 % (100/100). TBG was completed in 68 % (68/100; insufficient tissue 20 %; 20/100; declining ECOG PS 12 %; 12/100). Repeat tissue biopsies were avoided in 12 % (12/100) of patients due to available LBG reports. The median calendar days from LBG to receipt of genomic report was 21 days shorter for LBG (z = -6.8, p < 0.01) versus TBG, as a median (range: 1-104 days). For evaluable paired cases with both TBG and LBG available (n = 68), concordance was 90 % (61/68). LBG resulted in detection of 5 actionable variants. LBG (€1135) was less than half the cost of TBG (€2404). LBG also resulted in overall cost savings of €20,288 (reduced TBG; use of immunotherapy). CONCLUSIONS: LBG reduces the time to genomic diagnosis in patients with newly diagnosed NSCLC compared to tissue genotyping, identifies actionable variants not reported in tissue, and results in overall cost savings.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. O'Reilly D, O'Grady A, Hayes C, et al. Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study. Eur J Cancer. 2025. PMID: 40578048. doi:10.1016/j.ejca.2025.115582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。